Trials / Terminated
TerminatedNCT05169437
Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors
A Single-Arm Phase-II Study of Niraparib in Locally Advanced or Metastatic Solid Tumor Patients With PALB2 Mutations
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- Tempus AI · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to further evaluate the efficacy and safety of niraparib in patients with locally advanced or metastatic solid tumors and a pathogenic or likely pathogenic tumor PALB2 (tPALB2) mutation.
Conditions
- Solid Tumor
- Breast Tumor
- Colon Tumor, Malignant
- Lung Tumor
- Urologic Cancer
- Pancreatic Cancer
- Melanoma
- Metastatic Cancer
- Locally Advanced Solid Tumor
- Esophageal Cancer
- Endometrial Cancer
- Head and Neck Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Niraparib | Eligible participants will receive daily dosing of Niraparib. |
Timeline
- Start date
- 2022-03-15
- Primary completion
- 2024-08-06
- Completion
- 2024-08-27
- First posted
- 2021-12-27
- Last updated
- 2025-10-29
- Results posted
- 2025-10-29
Locations
80 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05169437. Inclusion in this directory is not an endorsement.